Background and Purpose-Inflammation is involved in the pathogenesis of large artery atherosclerosis, ischemic stroke, and Alzheimer dementia. However, the role of inflammation in cerebral small vessel disease and neurodegeneration remains poorly understood. We hypothesize that CRP (C-reactive protein) is associated with brain structural changes and may interact with amyloid to produce vascular and degenerative damage. We examined the association of CRP levels with imaging markers of cerebral small vessel disease and neurodegeneration. Furthermore, we studied the association of CRP with plasma Aβ (amyloid-β) levels and their joint effects with imaging markers. Methods-We included 2814 persons (mean age, 56.9 years; 44.8% women) from the Rotterdam Study with complete data on CRP and 1.5 T brain magnetic resonance imaging scans. Aβ levels were measured in a subsample (n=736). Markers of cerebral small vessel disease included lacunes, white matter hyperintensities, microbleeds, and enlarged perivascular spaces. Neurodegeneration was assessed by smaller volumes of gray matter, white matter, and hippocampus. Plasma levels of Aβ1-38, Aβ1-40, and Aβ1-42 were assessed using ELISA. Results-Higher CRP levels were associated with larger white matter hyperintensities volume (β=0.07; 95% CI, 0.00-0.13), increasing lacunar (rate ratios, 1.61; 95% CI, 1.19-2.19), enlarged perivascular spaces (rate ratios, 1.01; 95% CI, 1.00-1.03), and deep/infratentorial microbleeds (rate ratios, 1.30; 95% CI, 1.00-1.69) counts. People with high CRP levels had small gray matter volume. We also found significant interaction between CRP and Aβ such that among persons in higher tertiles of Aβ1-42, a strong association was observed between CRP and lacunar (P interaction, 0.004), enlarged perivascular spaces (P interaction, 0.002), and microbleed counts (P interaction, <0.001). Similarly, among persons in higher tertile of Aβ1-38, a strong association was observed between CRP and microbleed counts (P interaction, 0.004). Conclusions-Higher CRP levels were associated with subclinical markers of cerebral small vessel disease and neurodegeneration. This effect was augmented by an interaction between CRP and Aβ levels. Future longitudinal studies focusing on joint effects of CRP and Aβ on progression of magnetic resonance imaging markers and cognitive decline are warranted.
I nflammation has been implicated in the pathophysiology of atherosclerosis. 1 Several lines of evidence suggest that inflammation is a risk factor for coronary heart disease 2 and is also involved in the development of ischemic stroke 3 and Alzheimer dementia (AD). 4 CRP (C-reactive protein)-a nonspecific marker of inflammation-has been suggested to mirror the inflammatory process in the brain, thus allowing its utility as a potential biomarker. 5 Previous studies have shown that higher CRP levels are associated with increased risk of cerebrovascular disease and dementia as CRP increases the permeability of the blood-brain barrier. 6, 7 However, the role of CRP as a marker of cerebral small vessel disease (CSVD) and neurodegeneration remains poorly understood.
Noninvasive magnetic resonance imaging (MRI) markers of CSVD include lacunes, white matter hyperintensities (WMH), cerebral microbleeds, enlarged perivascular spaces (ePVS), and brain atrophy. 8, 9 A few studies have reported a relationship between higher levels of CRP with WMH and lacunes, but the results from these studies remain controversial. [10] [11] [12] [13] Two studies were unable to find an association between higher levels of CRP with severity of CSVD. 10, 14 By contrast, another study reported an association of CRP with severity and progression of WMH, whereas no association was observed with prevalent and incident lacunes.
11, 12 A recent study has reported higher levels of CRP among persons with microbleeds compared with those without. 13 These findings suggest that the association pattern between CRP and each marker of CSVD is likely to be different. However, studies investigating the association between CRP and whole spectrum of CSVD markers are scarce, leaving limited understanding of the impact of inflammation on different aspects of cerebral microvascular function. Apart from subclinical MRI markers, CRP was also found elevated in serum, cerebrospinal fluid, and brain tissue of patients with AD. [15] [16] [17] Limited data have suggested that CRP may be a pathogenic factor in AD progress along with Aβ (amyloid-β) oligomer initiation by activating complement-dependent destruction and propagating other inflammatory responses leading to vascular damage and neurodegeneration. 18, 19 Although CRP is associated with AD and influences Aβ production (specifically Aβ1-42) in one study, 20 the relevance of CRP and Aβ1-38 in cognitively normal individuals has not been studied previously. Aβ1-38 is reported to be present in the cerebral vessels of AD and is considered to be a sensitive and specific biomarker to diagnose AD over other non-AD dementias. 21, 22 Because both CRP and Aβ1-38 are elevated in AD pathology, it is reasonable to assume that higher CRP levels may also be associated with increased concentrations of Aβ1-38. Given the effects of CRP and Aβ on the vasculature and their common involvement in inflammation in AD development, the interaction of the 2 factors is of interest to better understand their joint contribution on structural brain changes.
Hence in this study, we examined whether higher levels of CRP are related to markers of CSVD (lacunes, WMH, cerebral microbleeds, and ePVS) and neurodegeneration (gray matter, white matter, and hippocampal volumes) in a large population-based setting. Furthermore, we examined the association of CRP with plasma Aβ levels, including Aβ1-38, Aβ1-40, and Aβ1-42, and their interaction in relation to MRI markers in a subsample of the Rotterdam Study (RS).
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population
The RS is a population-based prospective cohort study among middle age and elderly persons living in the Ommoord district in the city of Rotterdam, the Netherlands. For the current analyses, we focused on the third cohort (RS-III; 2006-2008) because of availability of CRP and Aβ levels in blood. Persons with prevalent dementia were excluded from this study. 23 Of 3932 persons, 3276 were eligible for MRI scans. Of 3276 persons, 2956 underwent brain MRI (response 90%). Individuals with incomplete scans and cortical infarcts were excluded (n=33) giving a sample of 2923 persons. Individuals with missing CRP data were further excluded leaving a data set of 2814 persons for MRI analysis. Among these 2814 persons, plasma Aβ levels were measured in a subsample of 736 individuals of whom 353 persons had microbleeds matched on age and sex with those without microbleeds (n=383; Figure) as assessed for our previous study. 21, 24 The RS was approved by the medical ethics committee according to the Population Study Act Rotterdam Study and by the Ministry of Health, Welfare, and Sports of the Netherlands. Written informed consent was obtained from all participants before study recruitment.
Plasma Assessment

C-Reactive Protein
Nonfasting blood samples were collected in the evacuated containers. Plasma was collected after centrifugation for 10 minutes at 3000 rpm. Platelet-free plasma was obtained by centrifugation for 10 minutes at 10 000 rpm, immediately frozen in liquid nitrogen, and stored at −80°C. A rate near-infrared particle immunoassay (Immage Immunochemistry System; Beckman Coulter, Fullerton, CA) was used. This system measures concentrations from 0.2 to 1.440 mg/L, with a within-run precision of <5%, a total precision of <7.5%, and a reliability coefficient of 0.995.
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Aβ Levels
Blood samples were drawn in EDTA tubes for plasma collection. After centrifugation (2500g, +4°C for 20 minutes), plasma samples were stored at −80°C within 60 minutes of collection. Plasma levels of Aβ1-38, Aβ1-40, and Aβ1-42 were quantified by EUROIMMUN ELISAs. The range of concentration was 5.9 to 18.7 pg/mL for Aβ1-38, 67.6 to 161.8 pg/mL for Aβ1-40, and 46.6 to 55.6 pg/mL for Aβ1-42, and the average coefficient of variations of Aβ1-38, Aβ1-40, and Aβ1-42 in plasma samples were 11.0%, 5.7%, and 8.7%, respectively.
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Brain Imaging
Brain MRI scans were performed on a 1.5-T scanner (GE Signa Excite; GE Healthcare, Waukesha, WI) with multisequence protocol comprising 3-dimensional T1-weighted, 2-dimensional proton-density weighted, 2-dimensional fluid-attenuated inversion recovery and 3-dimensional T2*-weighted gradient recall echo images.
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Markers of CSVD
Lacunes were defined as lesions involving the subcortical regions, 3 to 15 mm in diameter, with low signal on T1-weighted image, a high 
Stroke
November 2018
signal on T2-weighted image, and a hyperintense rim with a center following cerebrospinal fluid intensity on fluid-attenuated inversion recovery. Cerebral microbleeds were graded as small, round to ovoid focal areas of hypointense signal intensity with blooming on 3-dimensional T2*-weighted gradient recall echo images. Microbleeds were classified according to their location into strictly lobar and deep/ infratentorial microbleeds (with or without lobar microbleeds). 21 ePVS were defined as ovoid or linear shape lesions visible as hypointense on T1-and hyperintense on T2-weighted images and considered dilated if the size exceeded ≥1 mm using the Rotterdam-Graz Dilated Virchow-Robin Spaces scale.
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Brain Tissue Segmentation
Image preprocessing and the tissue classification algorithm have been described elsewhere. 26, 28 Briefly, k-nearest-neighbor brain tissue classifier technique was used to classify voxels into cerebrospinal fluid, gray matter, normal white matter, and WMH, and volume (mL) was calculated from these measurements. Intracranial volume was the sum of the cerebrospinal fluid, gray matter, normal white matter, and WMH. Hippocampus volume was derived using a model-based automated procedure (Free Surfer, v.5.1.0) on T1-weighted images. 29 All the image processing were visually checked for performance to ensure validity and reliability across study.
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Covariates Assessment
Data on demographics and medical history were recorded through interview and physical examination at the study center. Blood pressure was measured in 2 readings using a random-zero sphygmomanometer in a sitting position, and the mean of both measurements was calculated. Mean arterial blood pressure was calculated as twothirds of the diastolic blood pressure plus one-third of the systolic blood pressure. 21 Serum total cholesterol levels were measured using an automated enzymatic procedure. Diabetes mellitus was defined as fasting blood glucose ≥7 mmol/L or receiving treatment for diabetes mellitus. Smoking was categorized into ever versus never smokers. Intake of anti-inflammatory medications (antirheumatic and immunosuppressive agents) was collected during medical interview and was dichotomized as yes/no. Intima-media thickness and carotid arteries plaque were measured using ultrasonography. Intima-media thickness was determined as the average of mean, near-and far-wall, providing the average of left and right common carotid intima-media thickness. 31 A carotid plaque was defined as 1.5-fold focal broadening of the intima-media relative to the adjacent segments, with protrusion into the lumen. A weighted plaque score was obtained by counting the sites where a plaque was visible and dividing this number by the total number of sites for which images were available. The result was multiplied by 6, the maximum number of sites. 32 For the current analysis, a score of ≥2 (moderate/severe) was classified as plaque present.
Statistical Analysis
We performed analyses with CRP levels categorized as tertiles, as well as with the logarithmic transformation (because of skewed distribution). Poisson regression models were constructed to determine the association between CRP levels (log-transformed and tertiles) and MRI markers of CSVD, that is, lacunes, ePVS, and cerebral microbleeds as count data with rate ratios (RR) and 95% CI. For the continuous variables, linear regression models were computed with WMH, gray matter, white matter, and hippocampal volumes as possible outcomes. All regression models were initially adjusted for age, sex, and subsequently for mean arterial blood pressure, total cholesterol, diabetes mellitus, smoking, and anti-inflammatory medications. The final models were additionally adjusted for markers of cerebrovascular atherosclerosis: intima-media thickness and carotid plaques.
To determine the association between CRP and Aβ levels in a subsample of RS-III, we again constructed linear regression models with CRP as determinant and Aβ1-38, Aβ1-40, and Aβ1-42 as outcomes. The models were adjusted in the similar fashion as described above. To demonstrate the independent effects of CRP on possible outcomes from age, we also entered a quadratic term (age and age 2 ) in all regression models. For the models with MRI markers as outcome, we further tested the interaction between CRP and Aβ by including the cross-product term of CRP×Aβ with the main effect terms of each variable in the models. To better understand and visualize these interactions, we examined the association of CRP and Aβ to MRI markers within tertiles of Aβ1-38 (≤15, 16-18, ≥19 pg/mL), Aβ1-40 (≤150, 151-170, ≥171 pg/mL), and Aβ1-42 (≤52, 53-57, ≥58 pg/mL) adjusting for similar covariates as mentioned previously. Statistical analyses were performed using SPSS V24, Inc.
Results
Characteristics of the study participants and the subsample for the Aβ analysis are shown in Table 1 . Higher levels of CRP (log-transformed) were associated with larger WMH volume, increasing lacunar counts, and lower microbleed counts. Region-specific analysis on microbleeds showed that higher CRP levels were associated with lower microbleed counts in strictly lobar regions and higher microbleed counts in deep/ infratentorial regions (Table 2) . Similarly, higher tertiles of CRP levels were also associated with increasing lacunar, ePVS, and lower microbleed counts in the lobar region and higher microbleed counts in deep/infratentorial regions independent of all covariates (Table 2 ). Higher levels of CRP were also associated with smaller gray matter volume with no association with white matter and hippocampal volumes (Table 3) .
In the subsample analysis, elevated CRP levels were associated with higher plasma Aβ levels, specifically Aβ1-38 isoform. No association was observed between higher levels of CRP and Aβ1-42 isoforms (Table 4 ). The interaction between CRP and Aβ1-38 and between CRP and Aβ1-42 was significant. Among persons in the higher tertiles of Aβ1-42, a strong association was observed between CRP and lacunar counts (RR of CRP with lacunar counts in third tertile of Aβ1-42, 1.07; 95% CI, 1.02-1.12; P interaction, 0.004) and ePVS counts (RR of CRP with ePVS in third tertile of Aβ1-42, 1.69; 95% CI, 1.19-2.39; P interaction, 0.002; Table I in the online-only Data Supplement). Similarly, among persons in higher tertile of Aβ1-38, the RR of CRP with microbleeds was significantly lower (RR of CRP with microbleeds in second tertile of Aβ1-38, 0.78; 95% CI, 0.02-0.33; P interaction, 0.002 and third tertile of Aβ1-38, 0.27; 95% CI, 0.14-0.53, P for interaction, 0.004), whereas the same effect was observed in all tertiles of Aβ1-42 (RR of CRP with microbleeds in first tertile of Aβ1-42, 0.89; 95% CI, 0.81-0.96; P interaction, 0.007; second tertile of Aβ1-42, 0.88; 95% CI, 0.82-0.97; P interaction, 0.007; and third tertile of Aβ1-42, 0.09; 95% CI, 0.03-0.25; P interaction, <0.001; Table I in the online-only Data Supplement).
Discussion
In this study, we found that higher CRP levels were associated with imaging markers of CSVD: larger WMH volume, higher counts of lacunes, ePVS, and deep/infratentorial microbleeds. Furthermore, people with high CRP levels had smaller gray matter volume. We also found evidence for interaction between CRP and plasma Aβ levels, with stronger associations between CRP levels and lacunes and ePVS among persons with higher Aβ levels.
Previous studies on CRP and CSVD have reported conflicting results, with some reporting no association between CRP and presence and severity of lacunes and WMH, 10, 14 whereas others have reported a link between elevated levels of CRP with WMH progression.
11,12 These inconsistent findings have been attributed to differences in the study populations with previous studies, including younger individuals, few smokers, and less burden of hypertension.
14 It was also suggested that CRP represents an important early stage in the development of large-vessel atherosclerosis instead of CSVD. In terms of ePVS, till today, no data exist on linking it with inflammation. Our findings add further to the previous reports by reporting an association between higher CRP levels with WMH, lacunes, and ePVS. These associations may be explained by a combination of following mechanisms: First, elevated CRP levels are a marker for arteriolosclerosis which involves vessel occlusion, altered cerebral autoregulation, and increased vascular permeability giving rise to WMH, lacunes, and ePVS. 33 Second, elevated CRP reflects large-vessel atherosclerosis. Carotid atherosclerosis has been associated with CSVD, which are caused by decreased cerebral blood flow and production of inflammatory mediators and free radicals that affect microvascular endothelium.
11 Third, increased levels of endothelial inflammatory markers (intercellular adhesion molecule, vascular cell adhesion molecule) have been reported in persons with CSVD. 34 CRP is reported to be actively involved in endothelial cell activation, which plays a key role in small-and large-vessel disease. 35 Finally, the inflammatory process itself may be a response to ischemic damage secondary to hypoperfusion which increases the susceptibility of the surrounding neurons to further tissue damage and development of CSVD.
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In addition, we also reported a link between elevated CRP and higher prevalence of microbleeds. 13 However, no specific association was previously observed with anatomically distinct microbleeds. In our study, we found that elevated levels of CRP were associated with lower numbers of lobar microbleeds but higher number of microbleeds in deep/ infratentorial regions. A possible explanation could be that CRP may be a sensitive marker of arteriolosclerosis, which is mainly involved in hypertensive vasculopathy resulting in deep/infratentorial microbleeds. A reverse association was observed between second tertile of CRP levels and deep/ infratentorial microbleeds which might be because of chance or small numbers of persons with deep/infratentorial microbleeds. However, lobar microbleeds are thought to be indicative of cerebral amyloid angiopathy, implying the presence of different inflammatory signaling cascades other than CRP. Previous pathological and experimental studies have noted activated macrophages, reactive astrocytes, and T-lymphocytes adjacent to cerebral vascular amyloid deposits with a broad inflammatory response, including complement, reactive oxygen species, and proinflammatory cytokines, such as interleukin 6, cluster of differentiation 40 ligand, and tumor necrosis factor α. 36 Unlike CRP where no association was reported with Aβ indicates amyloid-β; CRP, C-reactive protein; and IQR, interquartile range. 
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microbleeds, these inflammatory cascades may facilitate development of lobar microbleeds. Alternatively, chronically progressing ischemic neuronal and glial injury and ensuing inflammatory response promote microglial senescence, 37 which decrease the risk of developing lobar microbleeds. Future studies involving lobar microbleeds should focus on alternative markers of inflammation to unravel these mechanisms.
Our finding of higher levels of CRP on smaller gray matter volume is consistent with previous literature. It is reported that higher circulating CRP was inversely associated with regional gray matter and total brain volume. 38 In a community-based study, a cytokine-chemokine combination, including CRP and interleukin 6, was associated with severe cortical atrophy. 39 These associations have been attributed to the increased influx and decreased efflux of Aβ across the blood-brain barrier, as well as increased neuronal synthesis of Aβ directly in the brain. 40 Alternatively, inflammation may also directly contribute to the neurodegenerative pathways, such as inducing neuronal apoptosis, inhibiting hippocampal neurogenesis, and influencing synaptic plasticity. [41] [42] [43] Little attention has been paid to the association of CRP levels with AD pathogenesis. Evidence from a mouse model has suggested that infusion of CRP increases Aβ-related mRNA levels of amyloid precursor protein (APP), β-site APP-cleaving enzyme, and presenilins 1 and 2, as well as Aβ1-42 productions, suggesting that higher levels of CRP play a central role in Aβ formation. 20 Our study showed that elevated levels of CRP were associated with higher levels of Aβ1-38 in the plasma although no association was observed with Aβ1-42. We have previously shown that Aβ1-38 might be a sensitive marker of vascular pathology and related to markers of CSVD. 21 We postulate that CRP may facilitate Aβ1-38 formation which may be independent of Aβ1-42, leading to its secretion in the peripheral circulation. Furthermore, we also reported an interaction between CRP and Aβ1-38 and Aβ1-42, suggesting that Aβ modulates the association of CRP with CSVD specifically lacunes, ePVS, and microbleeds. These findings further confirm the previous study that CRP is a potential trigger of Aβ production, 20 leading to its deposition in the media and adventitia of cortical arteries, occlusion of capillaries, and hypoperfusion. 44 Although we reported association between CRP and gray matter atrophy in the previous section, the correlation between CRP and neurodegenerative markers was not modulated by Aβ. Our failure to find these associations might be because of age of our sample (middle-aged adults) as it is suggested that gray matter atrophy is greater in the elderly ≥80 years. 45 This age effect may have an impact on both CRP and Aβ levels, where their joint effect on brain volume is more obvious in later life.
Our results have some limitations. First, we did not exclude or adjust for several other inflammatory conditions, such as concurrent infection, rheumatologic disease, or pulmonary disease, which may have the potential to increase CRP levels in blood. However, because this is a population-based study, the influence of such diseases is estimated to be minimal. Second, we only examined CRP as inflammatory marker in our study. As mentioned earlier, other cytokines might also be important in addition to CRP. Moreover, cytokines are regulated and influenced by each other. Therefore, it would be also interesting to examine a more comprehensive panel of inflammatory markers to adequately describe association with brain measures. Third, Mendelian randomization analysis using CRP gene tagging single nucleotide polymorphisms may help to explain the causal association between CRP and possible outcomes. Fourth, as the subsample with amyloid levels was enriched with participants with cerebral microbleeds, these results limit the generalizability to a population-based setting. Strengths of the study include adjustment for anti-inflammatory drugs and atherosclerotic measurements, use of a sensitive ELISAs technique to measure Aβ levels, and use of a wide range of imaging markers to reflect CSVD damage and neurodegeneration. , sex, mean arterial blood pressure, cholesterol, diabetes mellitus, smoking, anti-inflammatory medications, carotid plaques, and intima-media thickness.
†P<0.05
Conclusions
In conclusion, we showed that CRP as a marker of inflammation may be involved in the pathophysiology of CSVD and neurodegeneration. This effect was further augmented by an interaction between CRP and Aβ levels. Further longitudinal studies are needed to determine the possible effects of inflammatory reactions in CSVD and neurodegeneration and their progression. We recommend that inflammation should be considered as a target for treatment in clinical trials so as to delay progression of subclinical brain damage and potentially cognitive decline. 
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